Abstract library

599 results for "therapeutic management".
#868 Role of 68Ga-DOTATATE PET/TC (68Ga-PET-CT) for the Management of Patients with Neuroendrocrine Tumors (NETs): Impact in Therapeutic Decisions of our Clinical Practice
Introduction: 68Ga-PET-CT has demonstrated a higher diagnostic accuracy than any other imaging procedures (CT/MRI/SRS). ARGENTUM group described their experience with 68Ga-PET-CT in eight patients with advanced Gastroenteropancreatic Neuroendocrine Tumors (ENETS 2011). Conclusion was that 68Ga-PET-CT enabled changes in the strategy of treatment in all cases. The impact of 68Ga-PET-CT on the therapeutic management in NETs is constantly under evaluation.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: MD Claudia Bestani
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#2882 Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results
Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Piotr Radojewski
#2046 Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?
Introduction: A proportion of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) referred to NEN expert centers need a histopathological revision.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Elettra Merola
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors
Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#896 Grading of Metastases in Digestive Neuroendocrine Tumors (NET): Interest for Clinical Management?
Introduction: Therapeutic strategy of NETs is highly dependent on tumor classification according to the WHO system. NETs are frequently classified based on the histological characteristics of the primary tumor associated with the ENETS grading, even for patients with metastases.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Marie-Françoise Heymann
Keywords: NET, grading
#1377 Metastatic Neuro Endocrine Tumors: Epidemiological Characteristics, Management and Prognostics Factors. Results from an Inter-Regional Network in France between Upper and Lower Normandy
Introduction: Metastatic neuro-endocrine tumors (MNETs) are rare and their management are complex. To standardize therapeutic strategies in France, a national network of clinicians (RENATEN) has been created, composed of 17 expert centres.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Doctor Maxime Lesouef
#2277 Neuroendocrine Tumors Committee of Reference Hospital: Decision-Making Process on the Diagnostic and Therapeutic Approach to Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers due to their rarity, heterogeneity and the lack of evidence about optimal clinical management.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Paula Jimenez-Fonseca
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed